The PCSK9 Inhibitor Conundrum
Medicine is at a crossroads; cardiology in particular. I saw this fact magnified at the American Society for Preventive Cardiology’s recent town hall on access barriers to PCSK9 inhibitors.
Tag: Cardiovascular|Cost Value|Innovation
